Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
David Steensma MD, FACP

David Steensma MD, FACP

Oncologist, David P Steensma LLC, Cambridge, Massachusetts

Dr. Steensma was most recently the Global Head of Hematology for the Novartis Institutes of BioMedical Research (NIBR), leading early development across hematology programs. Prior to joining NIBR, he was the Edward P. Evans Chair in MDS and director of the Center for Prevention of Progression at Dana-Farber Cancer Institute in Boston.


Former employment, Novartis

Minor equity: Bluebird, Arrowhead, Gilead, TwoSeventy, GamidaCell